The purposes of the Einstein Liver Research Center (LRC) are to provide strong leadership and direction, catalyze creative basic and translational liver-related research, sustain a collaborative state-of-the-art infrastructure ad provide tools and approaches to facilitate the discovery and translation of novel research findings into improvements in treatment and prevention of liver disorders. The Center supports a group of established investigators actively conducting quality research that relate to liver pathobiology and fit into one of our three research foci: 1) Liver Regeneration, Cell Growth Control and Repopulation of the Liver by Transplanted Cells;2) Pathobiology of Hepatic Transport and Trafficking;3) Hepatic Metabolism, Inflammation, and Steatohepatitis. By bringing excellent basic scientists into disease-related research, together with hepatologlsts interested in mechanisms of hepatic dysfunction, we believe that imaginative approaches to basic cell biology, pathophysiology, diagnosis, treatment and prevention of liver disease will emerge. Our basic philosophy has been and continues to be, to seek out expertise and help from each other in an open ended fashion in our quest for new understanding of liver structure-function and disease. Core facilities are: A) Animal Models, Stem Cells and Cell Therapy;B) Molecular Biology and Next Generation Technologies;C) Imaging and Cell Structure;D) Genetic Engineering and Gene Therapy;and an Administrative Core. A Clinical Component has been added to the Center provide a platform to bridge new basic research findings to translational advances in the study and treatment of human liver diseases. The Center is directed by the Principal Investigator (Dr. Allan W. Wolkoff) and Associate Director (Dr. David A. Shafritz), governed by an Executive Committee and advised and reviewed by an external Scientific Advisory Committee. The importance of the Liver Research Center to the College of Medicine and hospital center has been reconfirmed by extensive renovation of existing facilities, updating of equipment, an endowment fund and recruitment of new faculty with resources provided by Dean Allen Spiegel, and Montefiore CEO Dr. Steven Safyer.

Public Health Relevance

It is estimated that over 30 million Americans have a liver disorder;further, liver disease is one of the ten leading causes of death in the United States. Although advances have been made in diagnosis and treatment of liver diseases, there is still much to be learned. The Liver Research Center at Einstein provides a multidisciplinary approach to the study of liver disease by integrating basic and clinical research efforts to foster development of new insights and paradigms.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK041296-26
Application #
8701592
Study Section
Special Emphasis Panel (ZDK1-GRB-8 (J2))
Program Officer
Podskalny, Judith M,
Project Start
1997-06-01
Project End
2019-06-30
Budget Start
2014-08-15
Budget End
2015-06-30
Support Year
26
Fiscal Year
2014
Total Cost
$1,252,500
Indirect Cost
$502,500
Name
Albert Einstein College of Medicine
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461
Walters, Ryan O; Arias, Esperanza; Diaz, Antonio et al. (2018) Sarcosine Is Uniquely Modulated by Aging and Dietary Restriction in Rodents and Humans. Cell Rep 25:663-676.e6
Liu, Zhongbo; Apontes, Pasha; Fomenko, Ekaterina V et al. (2018) Mangiferin Accelerates Glycolysis and Enhances Mitochondrial Bioenergetics. Int J Mol Sci 19:
Tekirdag, Kumsal; Cuervo, Ana Maria (2018) Chaperone-mediated autophagy and endosomal microautophagy: Joint by a chaperone. J Biol Chem 293:5414-5424
Zhao, Rongbao; Najmi, Mitra; Aluri, Srinivas et al. (2018) Concentrative Transport of Antifolates Mediated by the Proton-Coupled Folate Transporter (SLC46A1); Augmentation by a HEPES Buffer. Mol Pharmacol 93:208-215
Amengual, Jaume; Guo, Liang; Strong, Alanna et al. (2018) Autophagy Is Required for Sortilin-Mediated Degradation of Apolipoprotein B100. Circ Res 122:568-582
Schneider, Michael; Kumar, Vivek; Nordstrøm, Lars Ulrik et al. (2018) Inhibition of Delta-induced Notch signaling using fucose analogs. Nat Chem Biol 14:65-71
Iqbal, Niloy Jafar; Lu, Zhonglei; Liu, Shun Mei et al. (2018) Cyclin-dependent kinase 4 is a preclinical target for diet-induced obesity. JCI Insight 3:
Galsgaard, Katrine D; Winther-Sørensen, Marie; Ørskov, Cathrine et al. (2018) Disruption of glucagon receptor signaling causes hyperaminoacidemia exposing a possible liver-alpha-cell axis. Am J Physiol Endocrinol Metab 314:E93-E103
Shen, Ling; Liu, Yin; Tso, Patrick et al. (2018) Silencing steroid receptor coactivator-1 in the nucleus of the solitary tract reduces estrogenic effects on feeding and apolipoprotein A-IV expression. J Biol Chem 293:2091-2101
Dulyaninova, Natalya G; Ruiz, Penelope D; Gamble, Matthew J et al. (2018) S100A4 regulates macrophage invasion by distinct myosin-dependent and myosin-independent mechanisms. Mol Biol Cell 29:632-642

Showing the most recent 10 out of 451 publications